Article and Video CATEGORIES
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC by Dr. David Gerber
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
[powerpress]
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC Audio Podcast
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on